Altered Expression of Nonclassical HLA Class Ib Antigens in Human Renal Cell Carcinoma and Its Association with Impaired Immune Response

Human Immunology

Volumn 64, Issue 11, 2003, Pages 1081-1092

  Bukur, Jürgen ^b   Malenica, Barbara ^b   Huber, Christoph ^b   Seliger, Barbara ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

Immune response; Nonclassical HLA class I molecules; Renal cell carcinoma

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA G ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER IMMUNOLOGY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; INTERFERON PRODUCTION; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0242609900     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2003.08.350     Document Type: Conference Paper

References (47)

1. Reuter VE, Presti Jr. JC: Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 27:124, 2000.
2. Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, Bukowski R: Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50:2363, 1990.
3. Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, Bukowski R: Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 11:1, 1992.
4. Bernhard H, Maeurer MJ, Jaeger E, Wölfel T, Schneider J, Karbach J, Seliger B, Huber C, Storkus WS, Lotze MT, Meyer zum Büschenfelde KH, Knuth A: Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated interferon-gamma. Scand J Immunol 44:285, 1996.
5. Brandle D, Brasseur F, Weynants P, Boon T, van den Eynde B: A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 183:2501, 1996.
6. Brouwenstijn N, Gaugler B, Kruse KM, van der Spek CW, Mulder A, Osanto S, van den Eynde BJ, Schrier PI: Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int J Cancer 68:177, 1996.
7. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F: A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 162:1730, 1999.
8. van den Eynde BJ, Gaugler B, Probst-Kepper M, Michaux L, Devuyst O, Lorge F, Weynants P, Boon T: A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 190:1793, 1999.
9. Finke JH, Rayman P, George R, Tannenbaum CS, KoleNko V, Uzzo R, Novick AC, Bukowski RM: Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. Clin Cancer Res 7:940, 2001.
10. Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B: Gene transfer of the co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 50:242, 1999.
11. Luboldt H-J, Kubens BS, Rübben H, Grosse-Wilde H: Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56:826, 1996.
12. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M: Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51:6372, 1991.
13. Seliger B, Cabrera T, Garrido F, Ferrone S: HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3, 2002.
14. Paul P, Cabestre FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, Mercier S, Avril MF, Dausset J, Guillet J-G, Carosella ED: Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 59:1954, 1999.
15. Palmisano GL, Pistillo MP, Fardin P, Capanni P, Nicolo G, Salvi S, Spina B, Pasciucco G, Ferrara GB: Analysis of HLA-G expression in breast cancer tissues. Hum Immunol 63:969, 2002.
16. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P: Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196:266, 2002.
17. Polakova K, Krcova M, Kuba D, Russ G: Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res 27:643, 2003.
18. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A: Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159:817, 2001.
19. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R: HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99:609, 2002.
20. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller A: A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168:4772, 2002.
21. Seliger B, Abken H, Ferrone S: HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 24:82, 2003.
22. Ibrahim EC, Guerra N, Terrier Lacombe M-J, Angevin E, Chouaib S, Carosella ED, Caignard A, Paul P: Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61: 6838, 2001.
23. Ibrahim EC, Allory Y, Commo F, Gattegno B, Callard B, Paul P: Altered pattern of major histocompatibility complex expression in renal carcinoma. Am J Pathol 162:501, 2003.
24. Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B: Functional role of HLA-G upregulation in renal cell carcinoma. Cancer Res 63:4107, 2003.
25. Sobin LH, Witteking CH: International Union Against cancer. TNM Classification of Malignant Tumors (5th edition). New York: Wiley-Liss, 1997.
26. Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F: Expression of HLA-G in human tumors is not a frequent event. Int J Cancer 81:512, 1999.
27. Drexler I, Antunes E, Schmitz M, Wélfel T, Huber C, Erfle V, Rieber P, Theobald M, Sutter G: Modified vaccinia virus ANkara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res 59:4955, 1999.
28. Wélfel T, van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 224:759, 1994.
29. Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF: Monoclonal antibodies for analysis of the HLA system. Immunol Rev 47:3, 1979.
30. Pangault C, Amiot L, Caulet-Maugendre S, Brasseur F, Burtin F, Guilloux V, Drenou B, Fauchet R, Onno M: HLA-G protein expression is not induced during malignant transformation. Tissue Antigens 53:335, 1999.
31. Wainwright SD, Biro PA, Holmes CH: HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern. J Immunol 164:319, 2000.
32. Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, Morales P, Villena AA, Giacomini P, Natali PG, Frumento G, Ferrara GB, McMaster M, Fisher S, Schust D, Ferrone S, Dausset J, Geraghty D, Carosella ED: HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol 61:1177, 2000.
33. Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N: HLA-G mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11:1351, 1999.
34. Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J, Carosella ED, Rouas-Freiss N: HLA-G1 coexpression boosts the HLA class I-mediated Nk lysis inhibition. Int Immunol 13:193, 2001.
35. Bukur J, Seliger B: The role of HLA-G for protection of human renal cell carcinoma cells from immune-mediated lysis: implications for immunotherapies. Semin Oncol 2003. In press.
36. Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F: Expression of HLA G in human tumors is not a frequent event. Int J Cancer 81:512, 1999.
37. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED: HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 95:4510, 1998.
38. Drénou B, Le Friec G, Bernard M, Pangault C, Grosset J-M, Lamy T, Fauchet R, Amiot L: Major histocompatibility complex abnormalities in non-Hodgkin lymphomas. Br J Hematol 119:417, 2002.
39. Ugurel S, Reinhold U, Tilgen W: HLA-G in melanoma: a new strategy to escape from immunosurveillance? Onkologie 25:129, 2002.
40. Pascale P, Cabestré FA, Le Gal F-A, Khalil-Daher I, Le Danff C, Schmid M, Mercier S, Avril M-F, Dausset J, Guillet J-G, Carosella ED: Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 59:1954, 1999.
41. Willers J, Urosevic M, Laine E, Geertsen R, Kündig T, Burg G, Dummer R: Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression. J Invest Dermatol 117:1498, 2001.
42. Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED: HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA 100:1191, 2003.
43. Gobin SJP, Biesta P, de Steenwinkel JEM, Datema G, van den Elsen PJ: HLA-G transactivation by cAMP-response element-binding protein (CREB). J Biol Chem 277:39525, 2002.
44. Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 64: 315, 2003.
45. Lepin EJM, Bastin JM, Allan DSJ, Roncador G, Braud VM, Mason DY, van der Merwe PA, McMichael AJ, Bell JI, Powis SH, O'Callaghan CA: Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 30:3552, 2000.
46. Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, Valter MM, Angelisova P, Horejsi V, Strominger JL: Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci USA 99:16180, 2002.
47. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED: Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA 98:12150, 2001.